AFLAC (AFL) Q2 2024: Sumitas Launch Lifts Japan Sales 4.5%, Underpins Cross-Sell Strategy
Aflac’s Q2 was defined by disciplined expense control, robust capital deployment, and a notable product-driven sales lift in Japan. The Sumitas asset-formation product catalyzed a 4.5% sales increase, positioning the segment for cross-sell momentum even as underlying premiums declined. Management’s focus on margin, persistency, and capital flexibility sets up a measured but opportunity-rich back half of 2024.
Summary
- Japan Product Expansion: Launch of Sumitas drove new customer acquisition and cross-sell potential.
- Expense Ratio Discipline: Both Japan and US segments delivered multi-year lows in expense ratios, supporting margin strength.
- Capital Flexibility: Record $800M buyback and robust liquidity reinforce shareholder return capacity.
Business Overview
Aflac Incorporated is a leading provider of supplemental health and life insurance, operating primarily in Japan and the United States. The company earns revenue from insurance premiums and investment income, with Japan representing the largest segment—focused on third sector (medical, cancer, income support) and, increasingly, asset-formation products. The US segment emphasizes voluntary benefits, group life, and disability, with a growing presence in dental and vision.
Performance Analysis
Japan Segment: While net earned premiums declined due to internal reinsurance and paid-up policy effects, sales growth of 4.5% was achieved on the back of the Sumitas launch. Persistency remained solid at 93.3%, and the expense ratio hit a multi-year low of 17.8%, aided by reinsurance allowances and cost discipline. The benefit ratio rose moderately, reflecting product mix and favorable remeasurement gains, while pre-tax margin expanded sharply to 35.3%.
US Segment: Sales grew 2%, with persistency improving 50 bps to 78.7%. The benefit ratio increased, driven by intentional product value enhancements and normalization of claims post-pandemic. Expense ratio fell to 36.9%, reflecting operational leverage and scale in new platforms. The pre-tax margin reached 22.7%, among the highest in recent years, as the business mix shifted toward more profitable, lower-churn products.
- Japan Premium Decline: Internal reinsurance and paid-up policies weighed on net earned premiums despite new product traction.
- Margin Expansion: Both segments delivered notable pre-tax margin gains, with Japan up 490 bps and US at a multi-year high.
- Investment Income Tailwind: Net investment income in both markets benefited from higher yields and tactical portfolio actions.
Capital deployment was aggressive, with $800 million in share repurchases and a 19% dividend increase, reflecting strong liquidity and a focus on risk-adjusted returns. The investment portfolio showed resilience despite commercial real estate headwinds, and leverage remained below target corridors.
Executive Commentary
"We have continued our strategy of introducing life insurance products, including Sumitas, which we launched on June 2nd. This product offers policyholders an asset formation component with nursing care option. It was designed to attract new and younger customers while also introducing opportunities to sell them our core third sector products. While still very early, we are pleased with how our agencies have sold this product, which drove a 4.5% sales increase for the second quarter."
Dan Amos, Chairman, CEO, and President
"Our pre-tax margin for Japan in the quarter was 35.3%, up 490 basis points year-over-year, a very good result. Our expense ratio in Japan was 17.8%, down 170 basis points year-over-year, driven primarily by the expense allowance from reinsurance transactions and continued disciplined expense management."
Max Brodin, Executive Vice President and CFO
Strategic Positioning
1. Product Innovation and Cross-Sell in Japan
Sumitas, asset-formation life insurance, was launched to meet rising demand among younger Japanese for savings and flexible coverage. Beyond immediate sales, management positions Sumitas as a “hook” to cross-sell core cancer and medical (third sector) products, leveraging government policy tailwinds and asset accumulation needs. Early sales were strong, but leadership expects a normalization post-launch spike, with a focus on sustained cross-sell and customer lifetime value.
2. US Business Mix Shift and Persistency Focus
US segment strategy now emphasizes profitable, low-churn business, with underwriting discipline and product value enhancements. Group life, disability, and dental/vision platforms are scaling, with expense overruns expected to decline as these businesses mature. Persistency initiatives are already yielding improvement, and recruiting is prioritizing quality and productivity over raw headcount growth.
3. Capital Management and Shareholder Returns
Record buybacks and a 19% dividend hike underscore Aflac’s commitment to capital flexibility and shareholder yield. With $4.1 billion in unencumbered liquidity and strong solvency ratios, management is positioned to sustain both growth investment and tactical capital return, even amid yen volatility and investment market stress.
4. Expense and Margin Discipline
Expense ratios in both markets hit multi-year lows, driven by reinsurance, scale, and cost control. Management expects some seasonal uptick in H2, especially in Japan due to 50th anniversary campaigns, but structural cost improvements remain a focus, especially as new US businesses scale.
5. Investment Portfolio Resilience
Despite commercial real estate (CRE) headwinds, losses remain contained and Aflac continues to take a long-term view on intrinsic asset value. Tactical portfolio actions and favorable short rates provided a lift to net investment income, a trend management expects to continue into the second half.
Key Considerations
This quarter’s results highlight Aflac’s ability to balance growth, margin, and capital deployment in a complex macro and competitive environment. The strategic context is defined by:
- Japan Cross-Sell Opportunity: Sumitas is designed to seed new relationships, setting up future third sector sales and deeper customer engagement.
- Expense Ratio Sustainability: While Q2 ratios benefited from timing and reinsurance, guidance indicates some normalization, but structural cost discipline remains.
- US Platform Scaling: Dental, vision, and group life/disability are still running above-target expense ratios, with profitability expected to improve as scale is achieved.
- Capital Deployment Flexibility: Ample liquidity and robust capital ratios enable continued buybacks, dividend growth, and investment in new business lines.
- Persistency and Mix Shift: US persistency is improving, aided by product and distribution mix, which should support future premium stability.
Risks
Key risks include competitive pricing in Japan’s third sector, particularly as rivals introduce lower-priced products, and the possibility of lower-than-expected cross-sell conversion from Sumitas customers. Expense ratio improvement may be partially timing-driven, with H2 promotional spend and business mix potentially diluting Q2 gains. CRE portfolio valuation remains a watchpoint, though management expresses confidence in recovery values. Yen volatility and macroeconomic shifts in Japan could impact capital and reported results.
Forward Outlook
For Q3 2024, Aflac management guided to:
- Japan expense ratio trending toward the lower end of 19%–21% for the full year, with H2 uptick from anniversary campaigns.
- US expense ratio expected to rise in H2, with full-year range maintained at 38%–40%.
For full-year 2024, management maintained guidance, emphasizing:
- Disciplined capital deployment, with continued buybacks and dividend growth.
- Ongoing focus on profitable growth, margin preservation, and cross-sell leverage in Japan.
Management highlighted that Sumitas will serve as a catalyst for third sector sales, and that investment income tailwinds are expected to persist barring market shocks.
Takeaways
Aflac’s Q2 demonstrated a blend of product-driven growth, margin discipline, and proactive capital management, with Japan’s Sumitas launch providing a template for future cross-sell and customer acquisition.
- Japan Product Innovation: The Sumitas rollout proved the company’s ability to respond to changing consumer needs and government policy, while supporting cross-sell ambitions.
- Margin and Capital Strength: Multi-year low expense ratios and record buybacks reflect a focus on operational leverage and shareholder return, even as underlying premium trends remain mixed.
- Watch for Execution in H2: The sustainability of expense gains, cross-sell conversion from new customers, and CRE portfolio performance will be key for the remainder of 2024.
Conclusion
Aflac’s Q2 2024 was marked by strategic product launches, robust margin control, and assertive capital return, setting up a back half of the year focused on cross-sell execution and continued operational discipline. The company’s ability to leverage new products for deeper customer relationships and maintain capital flexibility positions it well, but execution on cross-sell and cost control will be critical watchpoints ahead.
Industry Read-Through
Aflac’s experience with Sumitas in Japan signals a broader trend toward hybrid asset-formation and protection products, especially as demographic shifts and government policy drive demand among younger consumers. The focus on cross-sell as a growth lever is likely to be replicated across the life and health insurance sector, particularly in mature markets. Expense control and capital deployment discipline are emerging as key differentiators, with insurers that can balance operational leverage and product innovation best positioned for margin resilience. CRE portfolio stress and investment yield management remain sector-wide themes, with Aflac’s tactical approach offering a potential playbook for peers navigating similar headwinds.